Shares of Novo Nordisk ended higher on Monday and extended gains in after-hours trading, while "Big Pharma" rival Eli Lilly ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

A proposal by the Biden administration to cover weight-loss medicines for obesity under Medicare has been axed by the White ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage ...

Novo Nordisk joined the many pharmaceutical companies pushing back on government-negotiated drug pricing in the United States.

The Trump administration has chosen not to finalize a rule proposed by the Biden administration that would have allowed ...

CMS keeps out LLY and NVO's obesity drugs from Medicare coverage. Medicare, at present, does not cover obesity drugs if they ...

The Centres for Medicare and Medicaid Services on Friday said that it did not move forward with a proposal put forward by the ...

April 14, 2025 Novo Nordisk warns consumers about counterfeit ... in the government's final reimbursement rates for 2026 Medicare Advantage health plans run by private insurers, more than double ...

The U.S. announced an increase in Medicare Advantage payment rates for 2026, exceeding expectations and affecting insurer ...

Extending coverage for the medications through Medicare could cost $35 billion over nine years, a congressional analysis ...